NA Proactive news snapshot: Lexaria Bioscience, Great Bear Resources, Thoughtful Brands, HighGold Mining ...

Lexaria Bioscience Corp (OTCQX:LXRP) (CSE:LXX), a global innovator in drug delivery platforms, has received its ninth US patent. In a statement Tuesday, the company said the new patent provides patent claims that protect the use of its DehydraTECH technology together with cannabinoids, nicotine, nonsteroidal anti-inflammatory drugs, or vitamins in mix-and-serve beverage formats. The patent is entitled "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof” -- and signifies another addition to Lexaria's first patent family. Great Bear Resources Ltd (CVE:GBR) (OTCQX:GTBAF) (FRA:0G6A) says it is very optimistic about the potential for high recovery of gold from mining its flagship Dixie asset in Red Lake as it updated on metallurgical testing at the site. In the famous Red Lake mining district, previous deposits have been dominated by free gold, namely the metal is not bound to or within sulphide minerals, typically yield very high recoveries. Great Bear has so far recorded 7,465 occurrences of visible gold in its drill core, while over 80% of drill holes into the LP Fault, Dixie Limb and Hinge zones have occurred as free gold, it noted. Thoughtful Brands Inc (CSE:TBI) (OTCQB:PEMTF) (FRA:1WZ1), a natural health products and e-commerce technology company, revealed on Tuesday that it had signed a supply agreement with Sweet Earth Holdings Corp (CSE:SE) (FRA:1KZ1), making it the exclusive CBD dog treat provider for its direct-to-consumer brand Nature's Exclusive. Sweet Earth Holdings, a vertically integrated hemp company, cultivates high-quality CBD products in Applegate Valley, Oregon. The agreement enables the Sweet Earth-produced CBD canine products to channel Thoughtful Brands' newly formed subsidiary Ecommerce Tech LLC, which runs a powerful e-commerce software platform aimed at acquiring new customers and providing great customer service. Sweet Earth canine products that will be sold under the Nature's Exclusive brand include the popular Beef and Cheddar Potato CBD Dog Treats. HighGold Mining Inc (CVE:HIGH) (OTCQX:HGGOF) told investors it has restarted drilling at its Munro-Croesus and Golden Mile properties in the Timmins gold camp in Ontario. In March this year, the explorer suspended drilling at Timmins due to the coronavirus (COVID-19) outbreak. At the time it said it had sunk 12 holes for 2,524 meters (m) of diamond drilling out of a planned 5,000m program. On Tuesday, HighGold said it had started a 3,500m drill program at the projects. Namaste Technologies Inc (CVE:N) (OTCMKTS:NXTTF) is entering the direct-to-consumer recreational cannabis market to sell products by licensed retailers via its online platform CannMart.com and its recently launched program VendorLink. The Toronto-based company announced Tuesday it is collaborating with cannabis firm High Tide Inc (CSE:HITI) (OTCQB:HITIF) that will see subsidiaries of both companies make recreational products available exclusively on CannMart.com for a one-year term, subject to renewals. Around 40 products earmarked for the recreational market will be made available to consumers in Saskatchewan, with weekly inventory changes and additional products to be made available, according to the firm. Marrone Bio Innovations Inc (NASDAQ:MBII) announced Tuesday that president and chief financial officer James Boyd is retiring. A national search process for a new CFO is underway, and Boyd will continue in both posts during the search process, the company said in a statement. “Jim has been a key member of the senior management team and a highly-regarded leader for the company over the last seven years,” said CEO Kevin Helash. Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) said on Tuesday that it has enrolled 75 patients for its multinational Phase 2b/3 human trial of its lead drug NP-120 (Ifenprodil) as a potential treatment for coronavirus (COVID-19) sufferers, which is 50% of its enrollment target. The Vancouver-based clinical-stage pharma company has been nimble — and unusual — in its hunt for a COVID-19 drug. It has taken a generic neurological drug that Sanofi developed in the 1970’s called Ifenprodil, which is approved for use in South Korea and Japan, and is attempting to repurpose it as a potential COVID-19 treatment. The company’s current study with a target of 150 patients will be completed by November 2020, with a planned data readout before the end of the fourth quarter this year. Ximen Mining Corp (CVE:XIM) (OTCQB:XXMMF) revealed it had started exploration drilling and trenching aiming at two targets at its Providence project near Greenwood in British Columbia. An excavator is being used at the first target - a historic mine adit -  where Ximen previously found 3.87 grams per ton (g/t) gold and 100 g/t silver from vein material sampled from the waste dumps. The second target is an area which hosts a showing of massive sulphide vein or skarn mineralization where a previous grab sample assayed 0.23% copper and 3.4 g/t silver. There is also a historic shaft on this zone. AIM ImmunoTech Inc (NYSEAMERICAN:AIM) announced positive results Tuesday from a pancreatic cancer Early Access Program (EAP) evaluating its drug Ampligen in the Netherlands. Professor Casper van Eijck and his team at Erasmus University Medical Center found a statistically significant positive survival benefit when using Ampligen in patients with locally advanced/metastatic pancreatic cancer after systemic chemotherapy.  Phunware, Inc. (NASDAQ:PHUN) has announced the release of its new mobile application software, Healthy Spaces to help individuals and businesses track and monitor personal health information while gathering together more safely through tech-enabled pre-screening, health and safety protocols. The fully-integrated enterprise cloud platform for mobile group, that provides products, solutions, data and services for brands worldwide, said Healthy Spaces is available for download on Google Play for Android and on the Apple App Store for iOS as well. Healthy Spaces allows users to build their own health profiles, which includes tracking, recording and evaluating key medical activities, habits and symptoms. Mobile application users can then create, manage and join groups across their professional and social networks for easy monitoring and check-ins. XPhyto Therapeutics Corp. (CSE:XPHY) (OTCMKTS:XPHYF) (FRA:4XT), a next-generation bioscience company, has provided an update on its oral disintegrating film (ODF) drug delivery programs. The group noted that its wholly-owned German subsidiary, Vektor Pharma TF GmbH is currently advancing two sublingual ODF development programs for the delivery of the active pharmaceutical ingredients (APIs) cannabidiol (CBD) and tetrahydrocannabinol (THC). Nabis Holdings Inc. (CSE:NAB) (OTCMKTS:NABIF) (FRA:A2PL) has announced the following changes to its board of directors: Mark Krytiuk has resigned from the board; Emmanuel Paul has been appointed chairman of the board; and James Tworek has been re-appointed to the board. As a results, Nabis said its board of directors is comprised of Shay Shnet, Tworek and Paul. Tworek and Paul comprise a special committee of independent directors with a broad mandate, including to take a more active role in the management of the company, and to continue the Strategic Alternatives Review Process previously announced by the Company. As part of the Strategic Alternatives Review Process, the special committee remains focused on securing additional capital to meet the company's liquidity needs, including continuing engagement with the company's debtholders. The Strategic Alternative Process remains ongoing and there can be no assurance as to what, if any alternatives might be pursued by the company. Essex Minerals Inc (CVE:ESX) said Tuesday it has closed its non-brokered private placement, raising C$2.75 million in gross proceeds to fund its mineral projects and exploration expenses. The company issued 5 million common shares at C$0.55 each. All of the securities are subject to a hold period, which will expire January 22, 2021. Q BioMed Inc. (OTCQB:QBIO), a commercial-stage biotech company, has said its CEO Denis Corin has discussed the initial commercial uptake of Strontium89, its FDA approved drug for the non-opioid treatment of metastatic cancer in the bone in an interview with SmallCapVoice.com, Inc. Corin also added context and his insights into the other company news regarding the GMP production contract has been initiated for MAN-19, a clinical-grade therapeutic intended to treat complications caused by coronavirus (COVID-19). The Phase 1 clinical trial is slated to begin patient enrollment in February 2021. Corin said: “We believe we have created a highly valuable pipeline of assets we hope to advance towards the patient populations we intend to treat. We have spent the last five years building our pipeline and we expect that work to start to pay off now as we hit the revenue and clinical milestones we anticipate in the next quarter or two.” The full interview can be heard at: https://www.smallcapvoice.com/9-21-20-smallcapvoice-interview-q-biomed-qbio/.